A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

Abstract

BackgroundTo investigate the clinicopathological characteristics and the survival outcomes of invasive lobular carcinoma (ILC) patients compared to invasive ductal carcinoma (IDC) patients according to their molecular subtype.MethodsWe compared the clinicopathological characteristics, breast cancer-specific survival (BCSS) and overall survival (OS) between patients with IDC (n = 14,547) and ILC (n = 528).ResultsThe ILC presented with a larger tumor size, more advanced cancer stage, increased rate of hormonal receptor positivity, human epidermal growth factor 2 (HER2) negativity and mastectomy than the IDC. The ILC patients more frequently presented with the luminal A subtype, whereas the IDC patients more frequently presented with the luminal B, HER2-overexpression, or triple negative subtype. The BCSS and OS were not significantly different between the IDC and ILC for each molecular subtype.ConclusionsSimilar to IDC patients, molecular subtype should be considered when determining the prognosis and treatment regimen for ILC patients.

Associations between the standardized uptake value of 18F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma

“…Compared with IDCs, ILCs were more likely to be positive for ER and PR and less likely to overexpress HER2 and Ki-67. The results of the present study are consistent with previous studies [ 12 , 18 , 19 ].…”

“…These studies have primarily included invasive ductal carcinoma (IDC), which comprises 72% to 80% of all invasive breast cancers [ 11 ]. Invasive lobular carcinoma (ILC) is the second most common breast cancer after IDC and accounts for 5% to 15% of all breast cancers [ 11 , 12 ], but there is a lack of data associating the SUVmax and prognostic factors in ILC in the existing literature. ILCs have exhibited low FDG uptake in previous studies [ 3 , 4 , 7 - 9 , 13 - 15 ].…”

Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study

“…In agreement with the previous literature, we found that relative to ductal cancers, lobular cancers were less frequent among black versus white women [36–39], less frequent among younger women [22, 36–38, 40–43], but more common among premenopausal women after controlling for age [23–25]. As has been shown previously, we observed that 88% of lobular tumors in our study were Luminal A subtype, which closely matches previous studies of lobular tumors (~80–90%, [7, 8, 11, 15, 17, 44, 45]), and is considerably higher than the overall prevalence of Luminal A subtype among invasive breast cancers (50%, [6, 7]). We also found that ductal tumors displayed diversity in clinical subtype and contained a majority of the TN and HER2+ tumor types, as others have reported [7–17].…”

A nomogram for determining the disease-specific survival in invasive lobular carcinoma of the breast

“…ILC, which is also known as infiltrating lobular carcinoma, is the second-most-common histological type of breast cancer, and its incidence is increasing. [ 13 ] Although ILC is less common than invasive ductal breast cancer (IDC), the proportion of cases with ILC is gradually increasing. [ 14 , 15 ] ILC tumors have a better long-term outlook and tend to be less aggressive than IDC tumors, but they are inclined to metastasize to the genital tracts, the gastrointestinal system, and meninges, and additional more commonly transfer to atypical sites.…”